Moleculin publishes peer-reviewed Annamycin cardiac safety analysis: no cardiotoxicity in 90 patients across 5 trials

Moleculin Biotech, Inc.

Pooled analysis of 5 trials (3 AML, 2 metastatic STS): 90 patients treated, paired echocardiographic data for 78; mean LVEF 60.6% at baseline vs 60.0% post-treatment (p=0.84).
No association between cumulative Annamycin dose or patient age and LVEF change; serial ECGs, troponin I/T and global longitudinal strain showed no treatment-related cardiotoxicity.
Median cumulative Annamycin dose was 660 mg/m2, exceeding conventional anthracycline lifetime limits; analysis independently reviewed by a Cleveland Clinic cardio-oncology laboratory.
CEO Walter Klemp said the absence of detectable cardiac toxicity beyond traditional dose thresholds supports continued development of Annamycin as a potentially safer anthracycline.
Annamycin is currently being evaluated in Moleculin's MIRACLE clinical development program for relapsed or refractory AML.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.